The combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed in the first-line setting for NSCLC has already been approved. The CheckMate 227 trial is currently investigating the combination of durvalumab and the CTLA-4 inhibitor ipilimumab (Yervoy) in multiple diseases, explains Simon.

The combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed in the first-line setting for NSCLC has already been approved. The CheckMate 227 trial is currently investigating the combination of durvalumab and the CTLA-4 inhibitor ipilimumab (Yervoy) in multiple diseases, explains Simon.